Genk, Belgium – Aspect Analytics, a leading provider of software for spatial biology data analysis, today announced the successful closing of an oversubscribed 10 million euro Series A funding round. The investment will accelerate the company’s international expansion, support continued innovation, and reinforce its position as the leader in spatial multi-omic data integration and large-scale research collaborations.

The announcement coincides with a strategic leadership transition. Marc Claesen, co-founder and former CEO, will assume the role of Chief Technology Officer, leveraging his deep expertise in spatial biology, machine learning, and artificial intelligence to drive the company’s AI-powered analytical capabilities. Steven Verhoeven will take on the role of Chief Executive Officer, bringing extensive experience in scaling VC- and PE-backed life sciences and diagnostics companies globally.

A Unique Approach to Spatial Biology

Aspect Analytics provides a patented software platform that enables researchers to integrate data from multiple spatial technologies, delivering true multi-omics insights. The Weave platform is uniquely capable of analyzing data at scale and deciphering complex multicellular environments, providing pharmaceutical and academic researchers with critical insights to uncover novel targets, unravel drug mechanisms of action, and optimize clinical trial cohorts.

“Spatial biology is generating massive amounts of data but turning it into actionable insights is where the true value lies,” said Marc Claesen, CTO of Aspect Analytics. “Our high-end data analysis services and Weave platform remove critical barriers in spatial biology data analysis, management and visualization. This enables researchers to collaboratively integrate and interact with diverse datasets, analyze multicellular systems at scale, and leverage advanced AI/ML methods to uncover insights that were previously out of reach.”

Fueling Growth and Global Expansion

The Series A funding will support Aspect Analytics’ international expansion, continued product innovation, and delivery of unique, industry-leading capabilities to its customers. The round was led by PMV and Capricorn Partners, through their Capricorn Healthtech Fund II, alongside existing shareholders & management. Existing investors include Heran Partners, Gemma Frisius Fund and KU Leuven.

“As we enter this next chapter, our goal is simple: scaling Aspect Analytics’ impact in drug discovery,” said Steven Verhoeven, CEO of Aspect Analytics. “With this investment, Marc driving our technology, and our team’s expertise, we’re ready to expand globally, empower researchers to unlock breakthrough discoveries, and set the standard in spatial biology data analysis.”

‍

About Aspect Analytics

Aspect Analytics is a pioneering spatial biology software company that delivers multi-omic data integration, scalable analysis of complex cellular environments, and AI-driven insights. Their proprietary Weave platform helps pharmaceutical and academic researchers uncover novel biological insights and optimize clinical research worldwide.

About Capricorn Partners

Capricorn Partners is an independent European manager of venture capital and equity funds, investing in innovative European companies with technology as a competitive advantage. The investment team of Capricorn is composed of experienced investment managers with deep technology expertise and a broad industrial experience. Capricorn Partners is managing the venture capital funds Capricorn Chemistry Fund, Capricorn Digital Growth Fund, Capricorn ICT Arkiv, Capricorn Healthtech Fund, Capricorn Healthtech Fund II, Capricorn Industrial Biotech Fund and Capricorn Fusion China Fund. In addition it is the management company of Quest for Growth, quoted on Euronext Brussels, and the investment manager of Quest Cleantech Fund which is registered in Luxembourg.

About PMV

The Flemish investment company PMV is shaping the future of the Flemish economy. PMV finances promising companies from the very start, through to growth and internationalization. PMV offers tailor-made financial solutions to entrepreneurs with a good business plan and a strong management team. It does so with capital, loans and guarantees. It also realizes, with and for the government, and other partners, projects that are important for prosperity and well-being in Flanders. PMV has a portfolio with1.9 billion euros under management. More information via www.pmv.eu

About Heran Partners

Heran Partners is a Belgium-based specialist venture capital investor committed to creating transformative impact within the life sciences and healthcare industry. Heran Partners is driven by a dedicated team with strong scientific and entrepreneurial backgrounds and provides venture & growth capital accompanied by a strong network, expertise and mentorship. Heran Partners targets start-ups and scale-ups with a solid technology platform and strong market potential. We look for innovations that deliver enhanced treatments and care for patients, create actionable insights, or enable efficiency gains throughout the drug development process and during the patient journey.

About Gemma Frisius Fund

The Gemma Frisius Fund (GFF) is a seed capital fund established in 1997 as a joint venture between KU Leuven, KBC Private Equity, and BNP Paribas Fortis Private Equity. It combines the university's expertise in research and technology transfer with the financial and investment knowledge of both financial partners. GFF provides start-up capital in the early development stages of innovative, research-oriented spin-off companies in all technological fields and guides them through their growth process.